BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thomas CR Jr, Berkey BA, Minsky BD, Gaspar LE, Herskovic A, Rich TA, Gunderson LL. Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys. 2004;58:1405-1410. [PMID: 15050316 DOI: 10.1016/j.ijrobp.2003.09.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Lau SKM, Iyengar P. Implications of weight loss for cancer patients receiving radiotherapy. Curr Opin Support Palliat Care 2017;11:261-5. [PMID: 28914642 DOI: 10.1097/SPC.0000000000000298] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Shin HJ, Moon HS, Kang SH, Sung JK, Jeong HY, Kim SH, Lee BS, Kim JS, Yun GY. Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma: Is it a significant prognostic factor? Medicine (Baltimore) 2017;96:e9441. [PMID: 29390576 DOI: 10.1097/MD.0000000000009441] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys 2017;99:407-16. [PMID: 28871991 DOI: 10.1016/j.ijrobp.2017.05.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Cox S, Powell C, Carter B, Hurt C, Mukherjee S, Crosby TD. Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1. Br J Cancer 2016;115:172-7. [PMID: 27328311 DOI: 10.1038/bjc.2016.129] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
5 Créhange G, Conroy T. The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future? J Thorac Dis 2016;8:1014-8. [PMID: 27293806 DOI: 10.21037/jtd.2016.03.74] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Van Veer H, Moons J, Darling G, Lerut T, Coosemans W, Waddell T, De Leyn P, Nafteux P. Validation of a new approach for mortality risk assessment in oesophagectomy for cancer based on age- and gender-corrected body mass index. Eur J Cardiothorac Surg 2015;48:600-7. [PMID: 25564215 DOI: 10.1093/ejcts/ezu503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-14. [PMID: 24556041 DOI: 10.1016/S1470-2045(14)70028-2] [Cited by in Crossref: 207] [Cited by in F6Publishing: 99] [Article Influence: 25.9] [Reference Citation Analysis]
8 Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Dufour P, Kurtz JE, Noel G. Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer. Dis Esophagus 2014;27:560-7. [PMID: 23106980 DOI: 10.1111/j.1442-2050.2012.01441.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
9 Watkins JM, Zauls AJ, Kearney PL, Shirai K, Ruppert BN, Harper JL, Sherman CA, Aguero EG, Reed CE, Sharma AK. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Jpn J Clin Oncol 2011;41:334-42. [PMID: 21084436 DOI: 10.1093/jjco/hyq208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Conroy T, Yataghène Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103:1349-1355. [PMID: 20940718 DOI: 10.1038/sj.bjc.6605943] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
11 Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 2009;249:764-7. [PMID: 19387328 DOI: 10.1097/SLA.0b013e3181a38e9e] [Cited by in Crossref: 68] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
12 Conroy T. [Clinical case: should esophageal cancers still be operated on?]. Gastroenterol Clin Biol 2009;33:285-8. [PMID: 19304427 DOI: 10.1016/j.gcb.2009.02.013] [Reference Citation Analysis]
13 Seung SK, Smith JW, Ross HJ. Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer. Diseases of the Esophagus 2008;21:589-95. [DOI: 10.1111/j.1442-2050.2008.00822.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Ressiot E, Dahan L, Liprandi A, Giorgi R, Djourno X, Padovani L, Alibert S, Ries P, Laquière A, Laugier R, Thomas P, Seitz J. Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroentérologie Clinique et Biologique 2008;32:567-77. [DOI: 10.1016/j.gcb.2008.02.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
15 Créhange G, Bosset M, Fabrice L, Buffet-miny J, Dumas JL, Mercier M, Puyraveau M, Maingon P, Bosset JF. Tumor Volume as Outcome Determinant in Patients Treated With Chemoradiation for Locally Advanced Esophageal Cancer. American Journal of Clinical Oncology 2006;29:583-7. [DOI: 10.1097/01.coc.0000242346.25229.48] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
16 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
17 Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol 2006;8:22-30. [PMID: 16632436 DOI: 10.1007/s12094-006-0091-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
18 Vuong T, Szego P, David M, Evans M, Parent J, Mayrand S, Corns R, Burtin P, Faria S, Devic S. The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. Int J Radiat Oncol Biol Phys 2005;63:758-64. [PMID: 16199311 DOI: 10.1016/j.ijrobp.2005.02.042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
19 Seung SK, Smith JW, Molendyk J, Bader SB, Phillips M, Regan J, Louie J, Soo E, Seligman M, Ruzich J. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. Semin Oncol. 2004;31:13-19. [PMID: 15726517 DOI: 10.1053/j.seminoncol.2004.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]